Quarterly report pursuant to Section 13 or 15(d)

Note 4 - Acquisitions (Details Textual)

Note 4 - Acquisitions (Details Textual) - USD ($) $ in Thousands			8 Months Ended	9 Months Ended
	Aug. 01, 2018	Jul. 02, 2018	Mar. 31, 2019	Mar. 31, 2019	Mar. 31, 2019	Mar. 31, 2019	Mar. 31, 2018	Feb. 01, 2018	Jan. 02, 2018
Payments to Acquire Businesses, Net of Cash Acquired, Total				$ 272,286			$ 65,066
QT Holdings Corporation [Member]
Payments to Acquire Businesses, Net of Cash Acquired, Total		$ 20,404				$ 20,461
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High		51,000	$ 51,000	51,000	$ 51,000	51,000
Goodwill, Purchase Accounting Adjustments					3,800	3,792
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		$ 20,000	12,200	12,200	12,200	12,200
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles						(7,800)
Atlanta Biologicals [Member]
Business Acquisition, Goodwill, Expected Tax Deductible Amount									$ 0
Exosome Diagnostics, Inc [Member]
Payments to Acquire Businesses, Net of Cash Acquired, Total	$ 251,825		251,825
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	325,000		325,000	325,000	325,000	325,000
Business Acquisition, Goodwill, Expected Tax Deductible Amount	0
Goodwill, Purchase Accounting Adjustments			13,474
Exosome Diagnostics, Inc [Member] \| Trade Names [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			58,000	58,000	58,000	58,000
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles			58,000
Exosome Diagnostics, Inc [Member] \| Developed Technology [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	180,000		105,000	105,000	105,000	105,000
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles			(75,000)
Exosome Diagnostics, Inc [Member] \| Customer Relationships [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			2,300	$ 2,300	2,300	2,300
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles			2,300
Finite-Lived Intangible Asset, Useful Life				14 years
Exosome Diagnostics, Inc [Member] \| Developed Technology Rights [Member]
Finite-Lived Intangible Asset, Useful Life				15 years
Exosome Diagnostics, Inc [Member] \| Calendar Year 2020 EBITA Between $45 Million and $58 Million or Greater [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	250,000
Exosome Diagnostics, Inc [Member] \| Calendar Year 2022 EBITA for A New Instrument Product Between $54 Million and $70 Million or Greater [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	45,000
Exosome Diagnostics, Inc [Member] \| Calendar Year 2022 EBITA for Remaining Business Between $150 Million and $190 Million or Greater [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	$ 30,000
Eurocell Diagnostics, SAS [Member]
Business Acquisition, Goodwill, Expected Tax Deductible Amount								$ 0
Goodwill, Purchase Accounting Adjustments			13,500
Eurocell Diagnostics, SAS [Member] \| Trade Names [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			58,000	$ 58,000	58,000	58,000
Eurocell Diagnostics, SAS [Member] \| Developed Technology [Member]
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles			(75,000)
Eurocell Diagnostics, SAS [Member] \| Customer Relationships [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			$ 2,300	$ 2,300	$ 2,300	$ 2,300